Latest market price
23.43
+0.46+2.00%
Earnings
Up 2.0% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -4.04 | Insider Own | 3.43% | Shs Outstand | 69.37M | Perf Week | 6.10% |
| Market Cap | 1.59B | Forward P/E | — | EPS next Y | -3.02 | Insider Trans | -18.20% | Shs Float | 57.52M | Perf Month | -2.09% |
| Enterprise Value | 843.35M | PEG | — | EPS next Q | -0.92 | Short Float | 15.17% | Perf Quarter | -47.41% | ||
| Income | -253.00M | P/S | 79.67 | EPS this Y | — | Short Ratio | 4.23 | Perf Half Y | 11.07% | ||
| Sales | 20.00M | P/B | 4.92 | EPS next Y | — | ROA | -25.60% | Short Interest | 8.73M | Perf YTD | -4.01% |
| Book/sh | 4.67 | P/C | 1.97 | EPS next 5Y | — | ROE | -111.96% | 52W High | 68.62 -65.86% | Perf Year | -66.15% |
| Cash/sh | 11.68 | P/FCF | — | EPS past 3/5Y | — | ROIC | -22.48% | 52W Low | 8.73 168.38% | Perf 3Y | 294.67% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -46.76% -15.89% | Gross Margin | 22.79% | Volatility | 9.62% 6.46% | Perf 5Y | -21.76% |
| Dividend TTM | — | EV/Sales | 42.17 | EPS Y/Y TTM | — | Oper. Margin | -1089.06% | ATR (14) | 1.94 | Perf 10Y | 219.03% |
| Dividend Ex-Date | — | Quick Ratio | 10.01 | Sales Y/Y TTM | 42.86% | Profit Margin | -1350.73% | RSI (14) | 36.78 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 10.01 | EPS Q/Q | -76.81% | SMA20 | 0.55% | Beta | 1.06 | Target Price | 53.70 |
| Payout | 0.00% | Debt/Eq | 0.19 | Sales Q/Q | 20.00% | SMA50 | -32.53% | Rel Volume | 3.08 | Prev Close | 22.97 |
| Employees | 221 | LT Debt/Eq | 0.19 | Earnings | Nov 04 | SMA200 | -22.55% | Avg Volume | 2.09M | Price | 23.43 |
| IPO Date | Feb 05, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -48.37% 7.19% | Net Debt/EBITDA | — | Volume | 6,440,178 | Change | 2.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-15-26 | Reiterated | UBS | Buy | $95 → $48 |
| Oct-05-26 | Downgrade | Barclays | Overweight → Equal Weight | $60 → $28 |
| Oct-02-26 | Reiterated | RBC Capital | Outperform | $65 → $48 |
| Sep-30-26 | Reiterated | Goldman Sachs | Neutral | $46 → $31 |
| Sep-29-26 | Reiterated | Wells Fargo | Overweight | $60 → $75 |
| Jul-30-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | |
| Jul-30-26 | Reiterated | Barclays | Overweight | $65 → $60 |
| Jun-29-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $80 |
| Jun-25-26 | Reiterated | Mizuho | Outperform | $33 → $68 |
| Jun-18-26 | Reiterated | Leerink Partners | Outperform | $35 → $70 |
Latest News· Times ET
Nov-02-26
Nov-02-2611:55AM
07:05AM
Oct-30-26
Oct-29-26
Oct-28-26
Oct-15-26
Oct-13-26
Oct-13-2607:11PM
Oct-08-26
Oct-08-2604:15AM
Oct-07-26
Oct-06-26
Oct-06-2606:00PM
10:20AM
08:14AM
Oct-05-26
Oct-01-26
Company
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20 | 16 | 27 | 16 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 13 | 2 | 18 | 14 | — | — | — | — | — | |
| Gross Profit | 3 | 14 | 9 | 2 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 75 | 65 | 51 | 73 | — | — | — | — | — | |
| Research and Development | 131 | 141 | 144 | 215 | — | — | — | — | — | |
| Other Operating Expense | 1 | -4 | -2 | -3 | — | — | — | — | — | |
| Operating Income | -203 | -188 | -184 | -283 | — | — | — | — | — | |
| Interest Expense | 60 | 62 | 64 | 42 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 56 | 11 | 18 | — | — | — | — | — | |
| Net Income Before Taxes | -245 | -193 | -237 | -307 | — | — | — | — | — | |
| Income Taxes | 7 | 6 | 2 | 2 | — | — | — | — | — | |
| Consolidated Net Income | -253 | -199 | -240 | -308 | — | — | — | — | — | |
| Net Income From Continuing Operations | -253 | -199 | -240 | -308 | — | — | — | — | — | |
| Net Income | -253 | -199 | -240 | -308 | — | — | — | — | — | |
| EPS (Recurring) | -4.04 | -3.46 | -4.92 | -6.47 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.04 | -3.46 | -4.92 | -6.47 | — | — | — | — | — | |
| EPS (Diluted) | -4.04 | -3.46 | -4.92 | -6.47 | — | — | — | — | — | |
| EBITDA | -181 | -117 | -161 | -253 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 77.32 | 86.75 | 32.05 | 20.31 | — | — | — | — | — | |
| Gross Margin | 15.00 | 87.50 | 33.33 | 12.50 | — | — | — | — | — | |
| Operating Margin | -1,015.00 | -1,175.00 | -681.48 | -1,768.75 | — | — | — | — | — | |
| Net Margin | -1,265.00 | -1,243.75 | -888.89 | -1,925.00 | — | — | — | — | — | |
| Shares Outstanding | 66 | 58 | 49 | 48 | — | — | — | — | — | |
| Market Capitalization | 1,546 | 1,388 | 865 | 325 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director | Jul 02 '26 | Sale | 45.16 | 21,082 | 952,051 | 519,227 | Jul 07 |
| Kapusta Matthew C | CEO, Managing Director | Jul 02 '26 | Option Exercise | 19.39 | 21,082 | 408,780 | 540,309 | Jul 07 |
| Kaye Jack | Director | Jun 30 '26 | Option Exercise | 23.44 | 21,167 | 496,230 | 43,056 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 '26 | Sale | 46.42 | 30,000 | 1,392,600 | 148,235 | Jul 02 |
| Kaye Jack | Director | Jun 30 '26 | Sale | 46.44 | 21,167 | 983,030 | 25,996 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 '26 | Option Exercise | 5.59 | 10,000 | 55,900 | 178,235 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 26 '26 | Sale | 46.86 | 1,434 | 67,197 | 168,235 | Jun 30 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 '26 | Option Exercise | 31.71 | 28,716 | 910,584 | 547,943 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 '26 | Sale | 50.02 | 28,716 | 1,436,374 | 519,227 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 '26 | Option Exercise | 31.71 | 4,128 | 130,899 | 525,923 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 '26 | Sale | 50.00 | 6,696 | 334,800 | 519,227 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 '26 | Sale | 50.00 | 41,671 | 2,083,550 | 521,795 | Jun 22 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 '26 | Option Exercise | 31.71 | 4,656 | 147,642 | 563,466 | Jun 22 |
| Kapusta Matthew C | CEO, Managing Director | Jun 17 '26 | Sale | 44.32 | 164,429 | 7,288,061 | 558,810 | Jun 22 |
| Balachandran Madhavan | Director | Jun 17 '26 | Option Exercise | 24.97 | 11,685 | 291,806 | 54,939 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.